经左锁骨下动脉留置导管肝动脉化疗栓塞加灌注治疗结直肠癌肝转移疗效观察

目的评价经左锁骨下动脉留置导管肝动脉化疗栓塞加灌注治疗内科化疗无效的结直肠癌肝转移患者临床价值。方法50例结直肠癌肝转移患者均采用经左锁骨下动脉留置导管肝动脉化疗栓塞加灌注,共介入治疗124周期,化疗方案为奥沙利铂＋5-氟尿嘧啶,栓塞剂采用超液化碘油。所有患者每次介入治疗前均行增强CT测量肿瘤大小,检测肿瘤标记物（CEA,CA199,CA724）。采用RECIST标准评价疗效,Kaplan-Meier计算生存率。结果本组患者完全缓解（CR）2例（4%）,部分缓解（PR）15例（30%）,病变稳定（SD）10例（20%）,病变进展（PD）23例（46%）,总有效率（CR＋PR）34%（17例）。1年生存率82%,2年生存率30%。从诊断肝转移始中位生存期38个月,从介入治疗始中位生存期22个月,中位无进展生存期10个月。结论经左锁骨下动脉留置导管肝动脉化疗栓塞加灌注是治疗内科化疗无效结直肠癌肝转移患者的有效方法。     

下肢动脉硬化闭塞症的介入治疗

目的探讨局部灌注溶栓、经皮腔内血管成形(PTA)、内支架置入(ES)以及血栓旋切等微创手段在下肢动脉硬化闭塞症治疗中的临床应用价值。方法对32例下肢动脉闭塞症患者37支病变血管,根据其病程和病变血管的具体情况,局部灌注溶栓2例,单独PTA 2例,PTA ES16例,血栓旋切 ES12例,分期观察其疗效和并发症。结果25例症状明显缓解(78%),术后主干血管即时再通32支(86%),术后4周29支病变血管保持通畅(78%),术后3个月及半年的再通率分别为66%和63%;1例患者于术后1周死于急性心肌梗死,无其他严重并发症发生。结论腔内介入是治疗下肢动脉硬化闭塞症的有效安全途径,术后规范抗凝对于保持血管再通至关重要。     

肝肿瘤CT引导经皮射频消融重要并发症临床分析

目的分析肝肿瘤CT引导下经皮射频消融重要并发症种类、影像学表现及防治方法。方法本组共分析了326例原发性肝癌和肝转移瘤患者,合计458个病灶,共消融944次,随访时间6~48个月。结果共14例患者出现并发症,包括肝脓肿3例(0.92%),肝包膜出血2例(0.63%),肝功能衰竭2例(0.63%),肾功能衰竭1例(0.32%),阻塞性黄疸1例(0.32%),电极处皮肤烧伤1例(0.32%),气胸1例(0.32%),血胸1例(0.32%),结肠穿孔1例(0.32%),针道种植转移1例。结论 CT引导下经皮射频消融治疗肝肿瘤是治疗肝肿瘤安全方法之一,术前详细评估患者、术后早期发现并发症及应用合适方法治疗会减少并发症发生。     

对吻支架置入术治疗肾动脉狭窄1例

患者男,60岁,头晕10年。血压180~210mmHg/95~140mmHg。双侧肾动脉处可闻及血管杂音。血清肌酐为140μmol/L。彩超示右肾动脉最大流速为186cm/s,肾动脉主动脉流速比大于3.5;左肾动脉最大流速为183cm/s,肾动脉主动脉流速比大于3.5。DSA示:右肾动脉起始部狭窄,狭窄程度80%,长约10m     

下肢动脉硬化闭塞症介入治疗138例分析

对我院2002—02～2005—10下肢动脉硬化闭塞症（PDA）介入治疗138例分析如下。     

Combination chemotherapy of gemcitabine and cisplatin by double way plus implantation of radioactive seed 125I in treating stage Ⅲ non-small cell lung cancer

Objective To assess the therapeutic effect of combination chemotherapy of gemcitabine and cisplatin by double way plus implantation of radioactive seed 125I implantation in treating stage Ⅲ non-small cell lung cancer. Methods Sixty cases with stage Ⅲ non-small cell lung cancer were randomly divided into two groups with random number table. In group A (in interventional treatment group, n = 30),the gemcitabine 1000 mg/m2 and one third of the cisplatin 100 mg/m2 was given using seldinger technique for transcatheter bronchial arterial infusion chemotherapy on day 1. Two-thirds of the cisplatin 100 mg/m2 was infused in veins on day 2 and 3. The gemcitabine 1000 mg/m2 was infused in veins on day 8, 21 days for a period. In group B (interventional - 125I groups), the method of combination chemotherapy of gemcitabine and cisplatin was the same as in Group A. After ten days of arterial perfusion, 125I seeds were implantated, 21 days for a period. All patients received at least 2 cycles. The imaging evaluation of patients after treatment standards included complete remission (CR), partial remission (PR), stable (SD),progressive disease (PD), effective rate (CR + PR)/30 and clinical benefit rate (CR + PR + SD)/30.Non-parametric rank sum test was used to compare short-term effect of the two groups treatment of two cycles.x2 test was used to compare year survival, Kaplan-Meier method was used to calculate median survival,log-rank test method was used to difference between the groups. Results In group A, there were 17 PR,9SD and 4 PD. The overall response rate was 56. 7% (17/30) and clinical beneficial rate was 86. 7% (26/30). In Group B, there were 2 CR, 21 PR, 7 SD. The overall response rate was 76.7% (23/30) and clinical beneficial rate was 100% (30/30). There was significant difference between the two groups (P =0. 036). In group A, the 1 year survival rate was 46. 7% (14/30) and the 2 year survival rate was 36. 7%(11/30), median survival time (MST) was 10 months . In group B, the 1 year survival rate was 76. 7%(23/30) and the 2 year survival rate was 63. 3% (19/30) , median survival time (MST) was 27 months.There was a significant difference between two group in 1 year survival rate (P = 0. 017), 2 year survival rate (P = 0. 039) and median survival time (P = 0. 006). Conclusion The treatment effects of Ⅲ stage non-small cell lung cancer by gemcitabine and cisplatin combination chemotherapy with double way plus radioactive seed 125I implantation was better than gemcitabine and cisplatin combination chemotherapy with double way.     

肝动脉热灌注化疗栓塞联合射频消融治疗原发性肝癌的对照研究

目的 探讨经肝动脉热灌注化疗栓塞(TACE)联合射频消融(RFA)治疗原发性肝癌的价值.方法 回顾性分析80例Ⅰ～Ⅱ期的原发性肝癌患者.A组(热灌注TACE联合RFA)36例,采用Seldinger法插管入肝内肿瘤供血动脉,将吉西他滨1000 mg溶于1200 ml生理盐水,以设定温度51℃,0.8～1.0 ml/s的流速进行热化疗灌注,然后用吉西他滨200 mg+卡铂200 mg+超液化碘油进行化疗栓塞.B组(热灌注TACE)44例,与A组相同方案行热灌注TACE.每4周为一周期,A组连续2周期后间隔2周,对原病灶行全麻下RFA治疗,B组连续4周期治疗.治疗后按mRECIST标准行影像评价有效率,比较卡氏评分、近期疗效、甲胎蛋白(AFP)转阴率、生存率、中位生存期.结果 A组卡氏评分改善、AFP转阴率、近期有效率均优于B组(Z=-2.080,P=0.038;P=0.037;Z=-6.756,P＜0.001).1、2、3年生存率:A组分别为97％、92％、78％,B组分别为80％、70％、36％;中位生存期:A组43个月,B组29个月,差异均有统计学意义(P＜0.05).结论 热灌注TACE联合RFA可进一步提高原发性肝癌治疗效果.     

球囊暂时阻断颈内动脉在头颈部肿瘤切除中的应用

目的 探讨暂时性颈内动脉球囊阻断试验在头颈部肿瘤切除的术前价值.方法 32例头颈部肿瘤患者术前行肿瘤侧颈内动脉暂时性球囊阻断试验,阻断30 min,观察并记录球囊阻断前后神经系统的变化.球囊阻断后监测残端动脉压力;计算残端动脉压力与患者平均动脉压比值.阻断时无神经系统相关症状或残端压≥阻断前50％为阴性,出现神经系统相关症状或残端压＜阻断前50％为阳性.结果 32例患者中,30例阴性,2例阳性.2例阳性中,1例阻塞后患者出现神经症状,立即终止试验后患者症状消失;1例无神经相关症状,残端压40 mmHg.30例阴性患者中,2例行部分颈内动脉切除,7例结扎颈内动脉,21例保留颈内动脉,肿瘤均完整切除,患者无术后神经系统相关并发症.2例阳性患者均放弃手术切除:1例行粒子植入结合动脉内药物灌注治疗,1例行氩氦刀结合动脉药物灌注治疗.结论 暂时性球囊阻断颈内动脉试验简便易行.通过评价患者闭塞颈内动脉后有无神经系统症状及监测残端动脉压,有助于选择头颈部肿瘤治疗方式,可有效避免出现神经系统相关并发症.